Exelixis (EXEL) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Exelixis (EXEL) over the past year, gaining 74.9% versus a gain of 52.7%. Over five years, KRYS leads with a +571.8% price change compared with +170.5% for EXEL. Exelixis is the larger company by market cap ($14.90 billion vs $9.82 billion), about 1.5 times the size, while Krystal Biotech is growing revenue faster (+33.9% vs +7.0%).
On valuation, Exelixis trades at a lower forward P/E (14.2x vs 35.8x for Krystal Biotech). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 33.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | KRYS |
|---|---|---|
| Share price | $60.14 | $331.78 |
| Market cap | $14.90B | $9.82B |
| 1-day change | +1.90% | +1.37% |
| YTD return | +34.66% | +32.76% |
| 1-year return | +52.74% | +74.86% |
| 5-year return | +170.49% | +571.80% |
| P/E ratio (TTM) | 18.97 | 41.58 |
| Forward P/E | 14.18 | 35.80 |
| EPS (TTM) | $3.17 | $7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $389.13M |
| Revenue growth (YoY) | +6.98% | +33.94% |
| Net income (latest FY) | $782.57M | $204.83M |
| Gross margin | 96.39% | — |
| Operating margin | 37.59% | 41.45% |
| Net margin | 33.73% | 52.64% |
| 52-week high | $61.14 | $382.54 |
| 52-week low | $33.76 | $179.19 |
| Distance from 52-week high | -1.64% | -13.27% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -9.33% | +18.18% |
| Average volume | 2.34M | 381.18K |
| Shares outstanding | 247.78M | 29.60M |
| Employees | 1,077 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed EXEL by 22.1 percentage points over the past year.
- Krystal Biotech trades at a higher earnings multiple (41.6x vs 19.0x trailing P/E).
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 33.7 cents for Exelixis.
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs +6.98%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
EXEL vs KRYS FAQ
Which is bigger, Exelixis or Krystal Biotech?
Exelixis (EXEL) is larger, with a market capitalization of $14.90B compared with $9.82B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, EXEL or KRYS?
KRYS returned +74.86% over the past 12 months, compared with +52.74% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EXEL or KRYS?
EXEL has the lower trailing P/E at 19.0, versus 41.6 for KRYS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Exelixis and Krystal Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.